Pennington Study Demonstrates Long-Term Weight Loss Efficacy of Semaglutide

The long term data is reassuring.  We now have more evidence for semaglutide weight loss efficacy in older, sicker individuals.

Response: We showed:

1) Weight loss is robust, though slightly less that in the weight loss studies. We expect this because we were not pushing the doses to top-dose in all cases and because it was NOT a weight loss study.

2)We showed that the weight loss was maintained for 4 years. This observation period is twice as long as prior studies. 

3) We showed that all subgroups (age, sex starting BMI, race, ethnicity, baseline health indicators) could achieve robust weight loss. 

4) At 2 years, 12% of people on semaglutide reached normal weight status and more than 55% no longer qualified as having obesity BMI class, both observations much higher than placebo. What should readers take away from your report?

Response: The long term data is reassuring.  We now have more evidence for semaglutide weight loss efficacy in older, sicker individuals. There were no safety issues uncovered when we analyzed the data by BMI class. What recommendations do you have for future research as a result of this work?

1. We need to better understand the mechanism of reducing cardiovascular events. 

2. It will be important to determine if there is a role in primary prevention of cardiovascular events. 

3.  It will be important to see if other GLP-1 receptor agonists produce this benefit.

Any disclosures? I consult with a number of companies making drugs and devices and commercial weight management approaches.  Donna H. Ryan declares having received consulting honoraria from Altimmune, Amgen, AstraZeneca, Biohaven, Boehringer Ingelheim, Calibrate, Carmot Therapeutics, CinRx, Eli Lilly and Company, Epitomee, Fractyl, Gila Therapeutics, Ifa Celtics, Nestlé, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, Scientific Intake, Wondr Health and Zealand Pharma; she declares she received stock options from Calibrate, Epitomee, Scientific Intake and Xeno Biosciences.


Ryan, D.H., Lingvay, I., Deanfield, J. et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med (2024).

The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on May 15, 2024 by weightcontrol